Cell-specific adenovirus vector comprising EBV-specific promoter
View Patent ↗Replication-competent adenoviral vectors comprising an EBV-specific transcriptional regulatory element (TRE) operably linked to a gene required for adenovirus replication are provided. By providing for transcriptional initiating regulation dependent upon transcription factors that are only active in specific, limited cell types, virus replication can be restricted to particular target cells. The modified adenovirus may be used as a vehicle for introducing new genetic capability, particularly associated with cytotoxicity for treating neoplasia.
1. A replication-competent adenovirus vector comprising a first adenovirus gene essential for replication under transcriptional control of an Epstein Barr-Virus (EBV)-specific transcriptional regulatory element (TRE) comprising a sequence selected from the group consisting of a sequence upstream of the translational start codon for the LMP1 gene, wherein said sequence is SEQ ID NO:1, a sequence upstream of the translational start codon for the LMP2A gene, wherein said sequence is SEQ ID NO:2 and the Cp promoter sequence which is SEQ ID NO:3.
2. The adenovirus vector according to claim 1 , wherein said EBV-specific IRE comprises SEQ ID NO:1.
3. The adenovirus vector according to claim 1 , wherein said EBV-specific TRE comprises SEQ ID NO:2.
4. The adenovirus vector according to claim 1 , wherein said, EBV-specific TRE comprises the Cp promoter sequence, which sequence is SEQ ID NO:3.
5. The adenovirus vector according to claim 1 , wherein said EBV-specific TRE further comprises the FR enhancer sequence, which sequence is SEQ ID NO:4.
6. The adenovirus vector according to claim 1 , further comprising a second adenoviral gene co-transcribed under transcriptional control of said EBV-specific TRE.
7. The adenovirus vector of claim 1 , wherein said first adenoviral gene essential for replication is E1A or E1B.
8. A composition comprising:
a replication-competent adenovirus vector according to claim 1 and a pharmaceutically acceptable excipient.
9. An isolated host cell comprising the adenovirus vector of claim 1 .
10. The adenovirus vector according to claim 2 , wherein said EBV-specific TRE comprises an ED-L1 regulatory region which is nucleotides 64 to 70 of SEQ ID NO:1.
11. The adenovirus vector according to claim 4 , wherein said EBV-specific TRE further comprises the FR enhancer sequence, which sequence is SEQ ID NO:4.
12. A composition comprising:
a replication-competent adenovirus vector according to claim 5 and a pharmaceutically acceptable excipient.
13. An isolated host cell comprising the adenovirus vector of claim 5 .
14. The adenovirus vector according to claim 6 , wherein the second adenoviral gene is under translational control of an IRES.
15. The adenovirus vector of claim 7 , wherein E1A or E1B has a mutation in, or deletion of, its endogenous promoter.
16. The adenovirus vector of claim 15 , wherein E1B has a deletion of the 19-kDa region.